HUM vs CNC

For growth investors, Centene Corporation (CNC) is the stronger pick with 19.

4% revenue growth year-over-year, versus 10. 1% for Humana Inc. (HUM). Humana Inc. (HUM) offers the better valuation at 24. 3x trailing P/E (26. 8x forward), making it the more compelling value choice. Analysts rate Centene Corporation (CNC) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Centene Corporation is actually cheaper at 15.

7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Centene Corporation (CNC) delivered a total return of -18.

9%, compared to -44. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: CNC returned +74. 6% versus HUM's +52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Centene Corporation (CNC) is the lower-risk stock at 0.

39β versus Humana Inc. 's 0. 56β — meaning HUM is approximately 44% more volatile than CNC relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 94% for Centene Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Centene Corporation (CNC) is pulling ahead at 19.

4% versus 10. 1% for Humana Inc. (HUM). On earnings-per-share growth, the picture is similar: Humana Inc. grew EPS -1. 4% year-over-year, compared to -315. 8% for Centene Corporation. Over a 3-year CAGR, HUM leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Humana Inc.

(HUM) is the more profitable company, earning 0. 9% net margin versus -3. 4% for Centene Corporation — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HUM leads at 1. 1% versus -3. 9% for CNC. At the gross margin level — before operating expenses — HUM leads at 14. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Centene Corporation (CNC) trades at 15.

7x forward P/E versus 26. 8x for Humana Inc. — 11. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HUM: 2. 7% to $246. 00.

In this comparison, HUM (1.

5% yield) pays a dividend. CNC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Humana Inc.

(HUM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), 1. 5% yield). Both have compounded well over 10 years (HUM: +52. 9%, CNC: +74. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HUM is a mid-cap quality compounder stock; CNC is a mid-cap high-growth stock. HUM pays a dividend while CNC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.